Who is sponsoring NCT00740207?

NCT00740207 is sponsored by Bracco Diagnostics, Inc.

What drugs are being tested in NCT00740207?

Interventions in NCT00740207: VISIPAQUE 270, Isovue 250.

What condition does NCT00740207 study?

NCT00740207 studies Peripheral Arterial Occlusive Disease.

Is NCT00740207 still recruiting?

NCT00740207 is currently completed. Last updated 5 May 2011.

Are results published for NCT00740207?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2011-05-05 · How we verify

NCT00740207

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase IV Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)

Completed Phase 4 Results posted Last updated 5 May 2011

What this trial tests

Phase 4 trial testing VISIPAQUE 270 in Peripheral Arterial Occlusive Disease in 33 participants. Completed in 1 July 2009.

Timeline

1 September 2008

Primary endpoint
1 July 2009

1 July 2009

Quick facts

Lead sponsor	Bracco Diagnostics, Inc
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	diagnostic
Enrollment	33
Start date	1 September 2008
Primary completion	1 July 2009
Estimated completion	1 July 2009

Drugs / interventions tested

VISIPAQUE 270 (IODIXANOL) — full drug profile →
Isovue 250 — full drug profile →

Conditions studied

Peripheral Arterial Occlusive Disease — all drugs for Peripheral Arterial Occlusive Disease →

Sponsor

Bracco Diagnostics, Inc — full company profile →

Who can join

18 and older, any sex, with Peripheral Arterial Occlusive Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Level of Pain in the Lower Extremities Scored by the Participants on the Visual Analog Scale Following Intraarterial Administration of ISOVUE-250 or VISIPAQUE 270 in Peripheral DSA.
Time frame: Immediately prior to power injection run and again immediately following power injection run
Visual Analog Scale: Patients were asked to mark on a 10 centimeter line where their pain was in the lower extremity of interest, in relation to the 2 extremes: no pain (0) on the far left and worst pain (10) on the far right. Pain Severity Scale: (0) None = VAS Score 0; (1) Mild = VAS Score 1-3; (2) Moderate = VAS Score 4-6; (3) Severe = VAS Score 7-10. Patients were assessed immediately prior to

Sponsor's own description

The purpose of this study is to compare ISOVUE-250 and VISIPAQUE 270 for motion artifact and pain following intraarterial injection for peripheral DSA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Peripheral Arterial Occlusive Disease

Currently open trials in the same condition.

NCT07352800 — Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-thr · Phase 2 · recruiting
NCT05933720 — Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis. · NA · recruiting

Other Bracco Diagnostics, Inc trials

Trials by the same sponsor.

NCT06400004 — Lumason® Infusion vs. Bolus Administrations · Phase 3 · recruiting
NCT04453059 — Study With Oral Isovue in Abdominopelvic CT · completed
NCT04248153 — Optimal Timing of BR55 CEUS of the Ovaries · Phase 2 · terminated
NCT03779906 — Thyroid Function of Pediatric Subjects Following Isovue® Administration · Phase 4 · terminated
NCT03493464 — BR55 in Characterization of Ovarian Lesions · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00740207 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bracco Diagnostics, Inc
Last refreshed: 5 May 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00740207.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing